GC4711 is an analogue of avasopasem (GC4419), designed to have the same potential mechanism of action and similar pharmacokinetic properties.  GC4711 is under development as a lyophilized product to be administered as a 15 minute intravenous infusion.  We plan to develop GC4711 in combination with stereotactic body radiation therapy (SBRT) as a treatment for various cancers including lung cancer.